Found: 7
Select item for more details and to access through your institution.
Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management—An Updated Review.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. 1, doi. 10.3389/fonc.2020.00831
- By:
- Publication type:
- Article
Theragnostic in neuroendocrine tumors.
- Published in:
- Quarterly Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 65, n. 4, p. 342, doi. 10.23736/S1824-4785.21.03426-9
- By:
- Publication type:
- Article
Circulating hsa-miR-5096 predicts <sup>18</sup>F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1136331
- By:
- Publication type:
- Article
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 10, p. 3260, doi. 10.1007/s00259-021-05236-z
- By:
- Publication type:
- Article
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 1, p. 152, doi. 10.1007/s00259-020-04873-0
- By:
- Publication type:
- Article
177 Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6022, doi. 10.3390/cancers14246022
- By:
- Publication type:
- Article
Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis.
- Published in:
- Pharmaceuticals (14248247), 2021, v. 14, n. 5, p. 476, doi. 10.3390/ph14050476
- By:
- Publication type:
- Article